Spetzler David Baxley
Spetzler David Baxley, PRES, reported a transaction classified as exercise at Caris Life Sciences, Inc. involving 250000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 04, 2026
- Filing date
- Sep 04, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
CAI price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0002071953-26-000007 Stock Option
- Transaction date
- Sep 04, 2026 Filed Sep 04, 2026, 08:59 PM · 0d delay
- Shares
- 250,000 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 0 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 0
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
President
- F1
The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solel…
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.3200 to $25.3100, inclusive. The reporting person undertakes to p…
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.3200 to $25.3300, inclusive. The reporting person undertakes to p…
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5550 to $25.1200, inclusive. The reporting person undertakes to p…
- F5
Exercise of stock options before their expiration date.
- F6
The stock option is fully vested and exercisable.
0 other transactions
0 recent txs